The effect of spike mutations on SARS-CoV-2 neutralization. 2021

Chloe Rees-Spear, and Luke Muir, and Sarah A Griffith, and Judith Heaney, and Yoann Aldon, and Jonne L Snitselaar, and Peter Thomas, and Carl Graham, and Jeffrey Seow, and Nayung Lee, and Annachiara Rosa, and Chloe Roustan, and Catherine F Houlihan, and Rogier W Sanders, and Ravindra K Gupta, and Peter Cherepanov, and Hans J Stauss, and Eleni Nastouli, and , and Katie J Doores, and Marit J van Gils, and Laura E McCoy
Institute of Immunity and Transplantation, Division of Infection and Immunity, University College London, London NW3 2PF, UK.

Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines show protective efficacy, which is most likely mediated by neutralizing antibodies recognizing the viral entry protein, spike. Because new SARS-CoV-2 variants are emerging rapidly, as exemplified by the B.1.1.7, B.1.351, and P.1 lineages, it is critical to understand whether antibody responses induced by infection with the original SARS-CoV-2 virus or current vaccines remain effective. In this study, we evaluate neutralization of a series of mutated spike pseudotypes based on divergence from SARS-CoV and then compare neutralization of the B.1.1.7 spike pseudotype and individual mutations. Spike-specific monoclonal antibody neutralization is reduced dramatically; in contrast, polyclonal antibodies from individuals infected in early 2020 remain active against most mutated spike pseudotypes, but potency is reduced in a minority of samples. This work highlights that changes in SARS-CoV-2 spike can alter neutralization sensitivity and underlines the need for effective real-time monitoring of emerging mutations and their effect on vaccine efficacy.

UI MeSH Term Description Entries
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D011991 Receptors, Virus Specific molecular components of the cell capable of recognizing and interacting with a virus, and which, after binding it, are capable of generating some signal that initiates the chain of events leading to the biological response. Viral Entry Receptor,Viral Entry Receptors,Virus Attachment Factor,Virus Attachment Factors,Virus Attachment Receptor,Virus Attachment Receptors,Virus Entry Receptor,Virus Entry Receptors,Virus Receptor,Virus Receptors,Attachment Factor, Virus,Attachment Factors, Virus,Attachment Receptor, Virus,Attachment Receptors, Virus,Entry Receptor, Viral,Entry Receptor, Virus,Entry Receptors, Viral,Entry Receptors, Virus,Receptor, Viral Entry,Receptor, Virus,Receptor, Virus Attachment,Receptor, Virus Entry,Receptors, Viral Entry,Receptors, Virus Attachment,Receptors, Virus Entry
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000086663 COVID-19 Vaccines Vaccines or candidate vaccines containing SARS-CoV-2 component antigens, genetic materials, or inactivated SARS-CoV-2 virus, and designed to prevent COVID-19. 2019 Novel Coronavirus Vaccine,2019 Novel Coronavirus Vaccines,2019-nCoV Vaccine,2019-nCoV Vaccines,COVID 19 Vaccine,COVID-19 Vaccine,COVID-19 Virus Vaccine,COVID-19 Virus Vaccines,COVID19 Vaccine,COVID19 Vaccines,COVID19 Virus Vaccine,COVID19 Virus Vaccines,Coronavirus Disease 2019 Vaccine,Coronavirus Disease 2019 Vaccines,Coronavirus Disease 2019 Virus Vaccine,Coronavirus Disease 2019 Virus Vaccines,Coronavirus Disease-19 Vaccine,Coronavirus Disease-19 Vaccines,SARS Coronavirus 2 Vaccines,SARS-CoV-2 Vaccine,SARS-CoV-2 Vaccines,SARS2 Vaccine,SARS2 Vaccines,2019 nCoV Vaccine,2019 nCoV Vaccines,COVID 19 Vaccines,COVID 19 Virus Vaccine,COVID 19 Virus Vaccines,Coronavirus Disease 19 Vaccine,Coronavirus Disease 19 Vaccines,SARS CoV 2 Vaccine,SARS CoV 2 Vaccines,Vaccine, 2019-nCoV,Vaccine, COVID 19,Vaccine, COVID-19,Vaccine, COVID-19 Virus,Vaccine, COVID19,Vaccine, COVID19 Virus,Vaccine, Coronavirus Disease-19,Vaccine, SARS-CoV-2,Vaccine, SARS2,Vaccines, 2019-nCoV,Vaccines, COVID-19,Vaccines, COVID-19 Virus,Vaccines, COVID19,Vaccines, COVID19 Virus,Vaccines, Coronavirus Disease-19,Vaccines, SARS-CoV-2,Vaccines, SARS2,Virus Vaccine, COVID-19,Virus Vaccine, COVID19,Virus Vaccines, COVID-19,Virus Vaccines, COVID19
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody
D017354 Point Mutation A mutation caused by the substitution of one nucleotide for another. This results in the DNA molecule having a change in a single base pair. Mutation, Point,Mutations, Point,Point Mutations

Related Publications

Chloe Rees-Spear, and Luke Muir, and Sarah A Griffith, and Judith Heaney, and Yoann Aldon, and Jonne L Snitselaar, and Peter Thomas, and Carl Graham, and Jeffrey Seow, and Nayung Lee, and Annachiara Rosa, and Chloe Roustan, and Catherine F Houlihan, and Rogier W Sanders, and Ravindra K Gupta, and Peter Cherepanov, and Hans J Stauss, and Eleni Nastouli, and , and Katie J Doores, and Marit J van Gils, and Laura E McCoy
March 2021, Cell host & microbe,
Chloe Rees-Spear, and Luke Muir, and Sarah A Griffith, and Judith Heaney, and Yoann Aldon, and Jonne L Snitselaar, and Peter Thomas, and Carl Graham, and Jeffrey Seow, and Nayung Lee, and Annachiara Rosa, and Chloe Roustan, and Catherine F Houlihan, and Rogier W Sanders, and Ravindra K Gupta, and Peter Cherepanov, and Hans J Stauss, and Eleni Nastouli, and , and Katie J Doores, and Marit J van Gils, and Laura E McCoy
May 2021, Proteins,
Chloe Rees-Spear, and Luke Muir, and Sarah A Griffith, and Judith Heaney, and Yoann Aldon, and Jonne L Snitselaar, and Peter Thomas, and Carl Graham, and Jeffrey Seow, and Nayung Lee, and Annachiara Rosa, and Chloe Roustan, and Catherine F Houlihan, and Rogier W Sanders, and Ravindra K Gupta, and Peter Cherepanov, and Hans J Stauss, and Eleni Nastouli, and , and Katie J Doores, and Marit J van Gils, and Laura E McCoy
September 2020, Cell host & microbe,
Chloe Rees-Spear, and Luke Muir, and Sarah A Griffith, and Judith Heaney, and Yoann Aldon, and Jonne L Snitselaar, and Peter Thomas, and Carl Graham, and Jeffrey Seow, and Nayung Lee, and Annachiara Rosa, and Chloe Roustan, and Catherine F Houlihan, and Rogier W Sanders, and Ravindra K Gupta, and Peter Cherepanov, and Hans J Stauss, and Eleni Nastouli, and , and Katie J Doores, and Marit J van Gils, and Laura E McCoy
September 2020, Cell host & microbe,
Chloe Rees-Spear, and Luke Muir, and Sarah A Griffith, and Judith Heaney, and Yoann Aldon, and Jonne L Snitselaar, and Peter Thomas, and Carl Graham, and Jeffrey Seow, and Nayung Lee, and Annachiara Rosa, and Chloe Roustan, and Catherine F Houlihan, and Rogier W Sanders, and Ravindra K Gupta, and Peter Cherepanov, and Hans J Stauss, and Eleni Nastouli, and , and Katie J Doores, and Marit J van Gils, and Laura E McCoy
January 2023, Journal of medical virology,
Chloe Rees-Spear, and Luke Muir, and Sarah A Griffith, and Judith Heaney, and Yoann Aldon, and Jonne L Snitselaar, and Peter Thomas, and Carl Graham, and Jeffrey Seow, and Nayung Lee, and Annachiara Rosa, and Chloe Roustan, and Catherine F Houlihan, and Rogier W Sanders, and Ravindra K Gupta, and Peter Cherepanov, and Hans J Stauss, and Eleni Nastouli, and , and Katie J Doores, and Marit J van Gils, and Laura E McCoy
July 2021, The New England journal of medicine,
Chloe Rees-Spear, and Luke Muir, and Sarah A Griffith, and Judith Heaney, and Yoann Aldon, and Jonne L Snitselaar, and Peter Thomas, and Carl Graham, and Jeffrey Seow, and Nayung Lee, and Annachiara Rosa, and Chloe Roustan, and Catherine F Houlihan, and Rogier W Sanders, and Ravindra K Gupta, and Peter Cherepanov, and Hans J Stauss, and Eleni Nastouli, and , and Katie J Doores, and Marit J van Gils, and Laura E McCoy
January 2021, Cell host & microbe,
Chloe Rees-Spear, and Luke Muir, and Sarah A Griffith, and Judith Heaney, and Yoann Aldon, and Jonne L Snitselaar, and Peter Thomas, and Carl Graham, and Jeffrey Seow, and Nayung Lee, and Annachiara Rosa, and Chloe Roustan, and Catherine F Houlihan, and Rogier W Sanders, and Ravindra K Gupta, and Peter Cherepanov, and Hans J Stauss, and Eleni Nastouli, and , and Katie J Doores, and Marit J van Gils, and Laura E McCoy
January 2024, mBio,
Chloe Rees-Spear, and Luke Muir, and Sarah A Griffith, and Judith Heaney, and Yoann Aldon, and Jonne L Snitselaar, and Peter Thomas, and Carl Graham, and Jeffrey Seow, and Nayung Lee, and Annachiara Rosa, and Chloe Roustan, and Catherine F Houlihan, and Rogier W Sanders, and Ravindra K Gupta, and Peter Cherepanov, and Hans J Stauss, and Eleni Nastouli, and , and Katie J Doores, and Marit J van Gils, and Laura E McCoy
June 2023, bioRxiv : the preprint server for biology,
Chloe Rees-Spear, and Luke Muir, and Sarah A Griffith, and Judith Heaney, and Yoann Aldon, and Jonne L Snitselaar, and Peter Thomas, and Carl Graham, and Jeffrey Seow, and Nayung Lee, and Annachiara Rosa, and Chloe Roustan, and Catherine F Houlihan, and Rogier W Sanders, and Ravindra K Gupta, and Peter Cherepanov, and Hans J Stauss, and Eleni Nastouli, and , and Katie J Doores, and Marit J van Gils, and Laura E McCoy
January 2020, Computational and structural biotechnology journal,
Copied contents to your clipboard!